The Shkreli Pill
YouTube channel feed
Total Ideas
59
With Returns
36
Equal-Weighted Return
+3.73%
All Ideas (59)
59 TotalSell Call on SLS Due to Failing Drug and Delayed Clinical Updates
"I do think SLS will fail. I can't believe the stock's at five. I may have to get involved here. SLS is crazy. Oh, it's a 400% bar rate. Another special capper special. Please sell everything on SLS ASAP. this drug does not work and they're der they're not they're there haven't reported the study in years it's taking forever no redue tide is just intense I don't think so."
The speaker delivers a strong sell recommendation on SLS, arguing that the company's drug is not effective and its clinical study updates are excessively delayed. The low trading price, mentioned at five dollars, further intensifies the bearish sentiment, prompting immediate divestment.
Nvidia's Unstoppable Role in the AI Computing Revolution
"the success of Nvidia almost 5 trillion cap right now basically and I don't think going away anytime soon basically is you know telling people that compute is important and it's actually the most important thing in the world right now and that was never the case. Semiconductors are never truly that important and now they really are the lynchpin global economy."
The speaker highlights Nvidia's massive market cap and pivotal role, emphasizing that its explosive success underscores the central importance of computing in today's economy. This commentary suggests that Nvidia's strong performance is a key indicator of broader trends in AI and semiconductor demand.
Consider Shorting Nvidia at Key Resistance Levels
"Nvidia stock rising quite nicely here almost 195. Again, I'd consider short at 200 or 205 just because again the cynic in me says we knew this would happen. Who who listened to Jensen at GTC say we have $500 billion backlog or listen to OpenAI cut a deal with uh Nvidia for chips for shares and not think we were going to get here."
The speaker suggests a short trade on Nvidia (NVDA) if the stock reaches resistance near 200-205. The rationale is based on the current high price around 195, a sizable backlog reported at GTC, and deal signals from OpenAI, indicating that the current valuation might soon reverse.
Buy Call on AIOS as It Dips 50%
"Um, yeah. I'm [clears throat] looking at AIOS this morning. Adios down around 50%. Looks like a buy to me. Adios is weird because like the delta on what the company's worth is not that high. They have they were trading at cash. They have one drug that selling a little bit, but that's really the story of the company in a lot of ways is just like it's very easy to calculate what what it's worth."
The speaker explicitly calls for buying AIOS, noting its steep 50% decline and the fact that it is trading at cash, suggesting the stock is undervalued and presents an immediate trading opportunity.
Long Position on Palantir Recommended
"I like Palantir for trading on the long side. Palantir's always been pretty good to me."
The speaker expresses a bullish stance on Palantir, recommending a long position based on personal positive experience with the stock. The comment suggests confidence in the company's trading performance without providing a specific price target or timeframe but implies immediate action.
Palantir Attracts on Its Strong Fundamentals Despite Price Dip
"Palantir down 2%. Palantir's back to attractive levels. The label is fine for Levitus, I think. Yeah."
The speaker highlights that Palantir (referred to as Palantir) has dropped slightly but has reached an attractive valuation. They emphasize the company's strong product, team, and competitive moat, suggesting that despite the recent dip, the underlying fundamentals make it appealing for investors.
Long-Term Upside in Lilly's Alzheimer's Trial
"I just want to add and say that like I think I'm pretty excited to see how Lily's uh trial turns out as well. They're running a really long trial. Um I think uh Lily and Biogen both started really long-term clinical trials in Alzheimer's about five, six, seven years ago or something. And um know we hope to see actually a fiveyear topline readout in the near future."
The speaker expresses excitement about Lilly's long-term Alzheimer's trial, noting that both Lilly and Biogen initiated long-duration studies years ago. He points to a potential five‐year topline readout, suggesting that early intervention in Alzheimer's could offer substantial upside.
Potential Buy Signal on Palantir (PLTR)
"I'm not saying Palantir is you go out and buy it. I mean, I for me it's a beta vehicle that I can kind of trust. It's had a nice mean version property. The street likes it. It's kind of what people buy when the market's down because people like to go shopping and it shouldn't have too much negative beta. I probably overdid it on those calls, but I might jump back in. I might jump back in. 22 cents. What do you guys think? Jump back in. Jump back in. Jump back in."
The speaker discusses Palantir as a reliable beta vehicle during market downturns and suggests an actionable re-entry by urging listeners to 'jump back in,' indicating a bullish trade call despite the lack of a formal price target.
Shorting AVXL Ahead of EMA Decision
"Up early for the European Union's uh European medical agency's comp committee's decisions for the month. In other words, AVXL watch. What's this? New York City. Ah, Dwave dropping quite a lot. I have a huge short position. Also, Regetti. Regetti is incredibly weak. Ion Q as well. I have AVXL puts. So, I'm short AVXL options are not open. Obviously, options markets don't open till 9:30."
The speaker outlines a trade call by taking a short position in AVXL via put options, driven by the upcoming EMA committee decision. The rationale centers on market weakness and the timing of the EMA announcement, suggesting bearish sentiment towards AVXL in the near term.
Short Trade Call on Anavex as Drug Data Falters
"Um, so I think the November are in play. Um, you know, the December are like 99% chance it's in play. I think the stock's going to cash value. Cash value here is probably around a dollar, and when we get their latest cash figures, I'd estimate around 75 cents a shareish. But I do think, you know, they're going to try to get re‐examined and possibly kick this can down the road to next year, yet the reality is I do think the jig is up. Now, if they somehow did get an EMA approval, I certainly think that the doctors won't pay for it or that the countries won't reimburse it — though in that scenario I could see the stock doubling, maybe going to 12."
The speaker expresses a high-conviction trade call on Anavex, arguing that the flawed clinical trial data and questionable analysis indicate the stock is destined to fall to its cash value—around $1 per share. Although acknowledging a remote upside if EMA approval were miraculously secured, the core view is bearish and suggests a short position using options in the November and December cycle.
Short Call on AVXL Anticipating EMA Negative Opinion
"I think and I'm going to go out on a limb here that we see the stock go to a dollar tomorrow. Why? I think that CHMP will render its opinion in the meeting minutes and they'll explain that they don't believe this drug works and the new clinical trial is warranted. But if that doesn't happen, I think it's it's closer to 7525. Uh but I acknowledge that, you know, there is a 25% chance that we see this on December 12th. Either way, it's toast. There isn't a person in the right mind if they've ever looked at clinical trials for more than a year or two which the CHMP is, frankly, one of the strictest groups out there."
The speaker lays out an aggressive short position on AVXL, predicting a drastic drop driven by an imminent negative EMA decision. The call is supported by anticipated regulatory disapproval and poor clinical trial data context, with a specific expectation for the stock to fall sharply, potentially as soon as tomorrow.
Short Call on BBAI Due to Poor Company Fundamentals
"BBAI short some of that. Stock is uh this company, whole company is a joke. I actually interviewed somebody that used to work there and they were pretty dismissive of their career there. Oh, I'm already short a bunch of it. Okay, I'll take that."
The speaker issues an explicit short call on BBAI, citing poor company fundamentals and dismissive insider commentary as the rationale behind the decision. The trade is positioned as an aggressive short, taking advantage of what is viewed as a fundamentally weak stock.
Buffett's High Confidence in Berkshire Hathaway's Next CEO
"Greg has become more than high has met more than the high expectations I had for him when I thought he should be Bergkshire's next CEO. He understands many of our businesses and personnel far better than I do now. And he's a fast learner about matters many CEOs don't even consider. I can't think of a CEO, management consultant, academic, member of government, you name it, that I would select over Greg to handle your savings and mine."
Buffett expresses strong confidence in Greg's ability to lead Berkshire Hathaway, highlighting his deep understanding of the business and superior management skills compared to other potential leaders.
Palantir Great Company Commentary
"I don't know if I'm bullish or bearish. I mean, the two things seem in balance as markets tend to price uh everything incorrectly, right? Had a lot of good years over the years. I'm very fortunate, very lucky. It's hard to tell what'll happen to the future of any company. I don't think Palantir I mean Palantir is a great company, so it's it's hard to bet against great companies. Uh management's very very good. I mean, Bur's never created something valuable, you know. Who do you respect? Alex Carp or Michael Bur? I mean, Car made a huge business with his bare hands. Palantir is a movie, too. It's called Zero Dark 30, The Hunt for Osama Bin Laden. Don't worry about my relationship with ALC. Okay."
The speaker provides a bullish view on Palantir, emphasizing its strong management and overall company quality. He underscores that it is hard to bet against a great company, despite market uncertainties, suggesting a positive long-term outlook.
Beyond Meat: Doomed by Lack of Customers
"A company like Beyond Meat is absolute poo poo, right? It's it's terrible. They don't have any customers. Anybody who doesn't like meat isn't eating processed chemicals and anybody who likes meat isn't eating Beyond Meat. They've got no no customers. And I think a point that Martin brought up before which is very astute is like value isn't always defined as cigarette butts, Coca-Cas, buying things for 10 times uh free cash flow, right? Unless you can point to a turnaround, you're just playing musical chairs with a stock that has no real fundamentals."
The speaker strongly criticizes Beyond Meat, describing it as a company with fundamentally flawed operations due to a lack of true customers and unsustainable business fundamentals. Without a clear turnaround plan or catalyst, the speaker warns that the stock's valuation is unjustifiable and is likely to underperform.
Palantir is Undervalued Relative to Its Growth
"Palunteer's valuation is not bad. People don't understand it. I showed you DCF yesterday. People just fundamentally don't understand Palantir. If your growth is 68%, which is what Palantir's last quarter revenue growth rate is, the true operating leverage earnings growth, it's probably over 100%. So if your earnings are growing over 100% and it's even accelerating, maybe even going to be 200%, it's not going to be that surprising when Palantir is actually trading for around 40 times earnings, which for such a big grower and good management team is actually pretty cheap."
The speaker argues that Palantir (PLTR) is undervalued given its strong revenue growth and accelerating earnings, trading at around 40x earnings despite high growth rates. This commentary suggests that the market underestimates the potential upside for a robust, high-growth company, making it an attractive long-term opportunity.
Long Duolingo Trade Call via Selling Palantir
"I'm going to try going long dual lingo. I'm crazy. I'm crazy. Day trading buying power cannot be used to buy this security. What can I use? What can I use to buy this security? Stupid. You know what? I'm going to sell a little bit of Palanteer just to buy a little bit of Duolingo. Quantum Dolingo. Qingo. What do you guys think?"
The speaker issues an explicit trade call to go long on Duolingo by selling some Palanteer to free up margin. Despite the chaotic delivery, the call is actionable and signals bullish conviction on Duolingo, positioning it as a trade based on immediate buying power constraints and market momentum.
All In on Biohaven Trade Call
"We've gone uh all in on uh Biohaven along BHVN. This is a biotech company that got bad news today. But personally, I don't really think it was that bad news because they had this drug that they were going to try to get approval for, but it doesn't really work. So, the FDA rejected it, but most people thought it was going to get rejected. I don't think too many people thought it was going to be approved, but the stock is acting like it was their most important drug, which it most certainly is not. So, I kind of like it. In fact, I put a ton in my portfolio."
The speaker expresses a bullish stance on Biohaven (BHVN) despite recent FDA rejection of a drug, arguing that the market overreacted to the news. He emphasizes that the drug isn't central to the business and has consequently taken an aggressive buy position in his portfolio.
Nvidia Buy Opportunity Below 200 Amid Decline
"I want to buy some Nvidia below 200. Honestly, it's been nose diving. Shout out to my father-in-law. I started with 30K. Is that okay? Is that okay? Is that okay with you?"
Martin indicates an actionable buy trade for Nvidia (NVDA), with a target entry below 200 due to its sharp decline. He suggests this price point as an attractive opportunity amidst the stock's current drop.
Explicit Short Position on AMD Through Manual Market Making
"Now, we're going to short it again. As simple as that. That's me on the NBBO. National best bid and offer for any noobs. Am I out? Am I out? I'm actually out. Okay, I'm out. AMD, where do we short? 24. Okay. Okay, where are we? Where are we? Are we short? We're short. 24725. Some real manual market making right here."
Martin executes an explicit short trade call for AMD, detailing his entry around 247. He emphasizes a hands-on approach with manual market making indicating high conviction in a bearish move.
Low-Conviction Biohaven Buy with Potential Doubling
"I bought a little Biohaven. I bought a new drugtock. I mentioned it in Goodell. I'm not saying it's like high conviction just yet, but if you want to join Godell, you can check out what it is. Little biotech company. I think, you know, it could double."
Martin reveals that he has initiated a small position in Biohaven (assumed ticker BHVN) suggesting a potential doubling in value, although he qualifies the move as low conviction.
Bearish Trade Call on BTQ
"See the number on the upper right corner 200,000 account value represents up 400%. Which is about a 5x for anybody. Going to short some BTQ. Rotate a little bit of the well-known quantum stocks more into like BTQ just because it's it's kind of one of these stocks you're not afraid to short because it's such an irrelevant company."
The speaker recommends a short trade on BTQ, arguing that among quantum stocks, BTQ is particularly irrelevant and vulnerable. He supports his call by highlighting his overall high account gains and a strategic rotation away from overvalued names.
Bullish Trade Call on Palantir
"All right. Palanteer is uh I think it's all eyes on Palunteer. If Palanteer ends up today, I just I think kind of think it will. The oneeyed trader still going to buy a little more Palanteer getting irresponsible. This basically this is just beta by the way. I mean I don't have any alpha on Palunteer. I just a little bit want to hedge out my my beta risk."
The speaker expresses a bullish stance on PALANTEER, indicating he plans to buy more if the stock performs well today. His rationale centers on capturing a short-term move, while noting his position serves mainly as a beta hedge rather than generating standalone alpha.
Potential Long Trade on CURE if FDA Reverses
"I think the FDA will chicken out and give them approval. And in some ways, this is almost a good thing for them because now it forces the issue since the stock was at 60 before and it was still like 50/50 what the FDA would do. So like now if the FDA changes their mind, we kind of should be going to 100 plus. And I think the FDA will change their mind. So it's kind of a great long. I still might buy some up here. It's up here and down here at the same time."
The speaker outlines an actionable trade call on CURE, suggesting that if the FDA reverses its current stance, the stock—which had been trading around 60—could surge above 100. The speaker expresses high conviction in a favorable FDA decision and indicates a readiness to accumulate on any price dislocation.
Buying Extended Hours on Sarepta Amid Approval Risk
"But here, let me buy some extended hours. This is kind of a known binary risk for Serupa, but I don't think there was a conditional. There's accelerated approval. Is that the same as conditional? I think it is. Right. Okay, let me see if I could buy some more. They bought some more at 1844. Wow. Good old Serupa. 1779. Raise the bid to 18 uh 1835."
The speaker explicitly initiates a buy order on Sarepta (represented as 'Serupa') during extended hours, suggesting confidence in the accelerated approval process despite known binary risk. The trade call is based on the belief that the approval risk is manageable and the price levels present a buying opportunity.
Visa's Impressive Margins and Transparency
"How does Visa grow, man? Visa's got the only company with 98% gross margins, 70% operating margin. They don't even try to obscure earnings. How could they? They spend more on their their audit they spend running their service. It's like the greatest business ever."
The speaker praises Visa for its exceptional gross and operating margins and its transparent approach to earnings, highlighting a fundamental competitive strength.
Walmart Overvaluation and Lack of Growth
"Okay, so Walmart really is 37 times earnings. Walmart's not growing, bro. What market is this? What What market are we in that Walmart's 37 times? Feel like Joe Biden. Come on, man. Yeah, I don't know, man. Google's at 25 times and is growing. Walmart's at 37 times. It's not growing. If I'm going to buy something that's not growing, give me some Bergkshire. Give me some Berkshire Hathway or like Taiwan Semi at 19 times, Meta at 22 times. Meta's got, you know, a decent strategy for AI, even if they're a little behind."
The speaker criticizes Walmart for trading at 37x earnings despite a lack of growth, contrasting it with companies like Google, Berkshire Hathaway, Taiwan Semi, and Meta, implying that Walmart may be overvalued.
Initiating SPY Calls Amid Market Froth
"Millennium has underperformed the S&P 500. We'd like to redeem our entire investment from Citadel, Kensington, and Wellington funds immediately. What are we going to do with it? Well, first of all, sir, that's none of your business. But second of all, I'm going to buy some spy calls. That's right. And a good day to you."
The speaker outlines a scenario where underperformance leads to a decision to exit traditional investments and execute a position in SPY call options, explicitly stating a plan to buy calls as part of a gamma squeeze strategy. This direct trade call reflects a bullish stance on the broader market via SPY options.
Buy Nvidia Stock for Strong Growth
"You know, you buy back your stock if you think it's cheap, but what do you know about investing? If you knew anything about investing, you would have bought Nvidia stock. So, you know, it's just kind of this, you know, corporate America is terrible at strategy and mergers and acquisitions. And sometimes, you know, you'll get a CEO who's really good and they'll actually deliver the goods. Um, and they're just brilliant and they know how to do both. But investing traditionally is one thing, but then deciding, okay, this is a great company. I want to have a part of it. That's kind of a different job altogether."
The speaker criticizes inefficient capital allocation via expensive buybacks and emphasizes that a knowledgeable investor would have allocated funds to buy Nvidia stock instead. This serves as an explicit call to buy NVDA based on a view that strong management and strategy are key to long-term success.
Uncertainty Over Nvidia's Future Amid Mixed Catalysts
"Nvidia is really hard to tell what's going to happen. I mean, in some ways, it's going to, you know, it really depends on what this super cycle looks like, but will the cycle end? You know, could it be a 20-year super cycle? Quantum is rallying here a little bit. Nvidia, you know, making all-time highs at $211 now. I don't know why Nvidia is trying to sell the Quantum because I think that quite frankly, Quantum doesn't have the money to really help Nvidia too much."
The speaker offers a nuanced commentary on Nvidia, expressing uncertainty about its future trajectory amid a mix of robust market highs and confusing strategic moves, such as the sale of Quantum. The commentary reflects caution due to potential cyclicality and ambiguous catalysts.
Sell Signal on SPRB as Losses Mount
"Spruce is up from 30 bucks to 120. I don't know if what you think getting wrecked is, but okay. It's fallen a bit from where you bought it probably, right? I bought it at 30. Did you buy it at 200? Some of you guys seem a little overindexed, a little overinvested. Cut your losses for spruce. Please leave me alone."
The speaker criticizes investors who remain overexposed in SPRB after the stock has risen and then retreated, advising them to cut their losses rather than trying to average down. The tone is direct and implies that holding SPRB may lead to further downside.
Company Commentary on Nvidia's AI Moves
"Tough news alert. Nvidia will build AI supercomputers for US energy department announces total bookings of $500 billion. >> Oh, I didn't know they announced 500 billion in bookings. I must have muted that part of the call. Okay."
The speaker highlights Nvidia's announcement to build AI supercomputers, underlined by a massive $500 billion in bookings. Although not a direct trade recommendation, it offers investor color on Nvidia's significant activity in the AI and energy sector.
Sell Trade Call on INBX
"And INBX. Man, I sold that on Friday. Somebody in godell chat scared me."
The speaker explicitly states that he sold his position in INBX last Friday, citing a signal from chat that spooked him. This is an actionable sell trade call on INBX.
Caution on Overvalued Stable Coin Network Prospects for BTQ
"If somebody came to me and said, 'Martin, I want to make a stable coin network.' I said, 'Cool, man. Uh, you're doing a preede, you don't have much work yet done. Couple million maybe you spent, maybe you're doing a seed. What's the valuation?' If they said a million, I'm sorry, if they said a billion, I would slap them in the face. If they said 10 million, 20 million, I'd say, 'Okay, I'll kick in a million.'"
The speaker sharply criticizes the idea of launching a stable coin network at a high valuation. He implies that if the valuation reaches around a billion dollars, it is unacceptable, suggesting that the company, BTQ, should be valued at a much lower level before it is considered a viable investment.
Concerns Over Liver Toxicity Impacting Intellia (NTLA)
"Intellia down as we've discussed on liver toxicity. I think that severe liver toxicity can be very scary because the drug in question is not being given to lots and lots of people. So if it has a one in 100 or one in 200 chance of liver toxicity, that's not good. Severe liver toxicity, not just transient liver toxicity. There aren't too many CRISPR drugs, and all eyes are on making sure that they're doing everything for the first time in a unique way. So, it's definitely worrisome, especially for the rest of their drugs, because it's kind of the same drug over and over again, just with different genes."
A bearish commentary on Intellia (NTLA) highlighting severe liver toxicity risks associated with its CRISPR drug, suggesting that repeated issues across its product line could lead to further stock declines.
Short Call on Capricorn Therapeutics (CAPR)
"okay, so cash per share at Capricorn is 269. It's a good short. Make a little money. 50%ish. Maybe it'll go down to 214 and they have uh data coming out relatively soon here. Probably about two weeks. I like this guy."
An explicit trade call recommending a short position on Capricorn Therapeutics (CAPR) based on its current cash per share valuation and an anticipated data release in about two weeks.
Trade Call: Buy the Dip on BTQ
"I like BTQ. It's like BTC but quantum. Imagine if they got all the value of Bitcoin. The stock would be up a lot. I should buy some. Oh no, what happened? It's down a lot. I thought it was quantum Bitcoin. Why is it down? Why isn't it like quantum Bitcoin? The price looks low to me. It's only at 10. Maybe it'll go to 50. It's just a dip. Dip is normal. We buy a dip."
The speaker presents an actionable trade call for BTQ, highlighting that although the stock is trading at a low price of 10, it has the potential to rise to 50 if it captures the full value of quantum Bitcoin. The call is to buy the dip based on the perceived undervaluation.
Beyond Meat Not Worth the Investment
"I was watching this great video of this great investor from the children\'s investment fund PCI who basically says that 99% of stocks out there are not suitable for his portfolio. And it\'s like such a crazy thing to say, but when you stop and think about it, it\'s really true that there are only a couple percent of the companies in the world that are exceptional and worth investing in. Beyond Meat is not one of them, spoiler alert, but nor are most companies. So why would you want this in your portfolio? You want to make crazy gambles."
The speaker delivers a bearish company commentary on Beyond Meat, asserting that it is not one of the exceptional companies worth investing in. The commentary implies that Beyond Meat, as a startup with a questionable business model, is unsuitable for long positions and should be avoided by conservative investors.
Buy Call on SKH Highix
"I\'m looking at some Korean stocks and there\'s been a lot of movement in Korea on the AI kind of bubble. Korea is often wildly mispriced, usually awfully cheap. I guess my point is you should always be looking at how to expand your toolkit to new companies, geographies, and sectors. And like SKHix is a really, really good example where SKHix just makes the memory for Nvidia\'s chip. You might have missed the Nvidia rally because if you ask an AI engineer, what\'s the most important part of an Nvidia chip? It\'s actually the memory. And with one Google search or one ChatGPT question, you would learn that it\'s actually SKH Highix and Samsung. Just buying SKH Highix, it\'s gone parabolic."
The speaker highlights SKH Highix as an undervalued play in the Korean market, emphasizing its critical role in producing memory for Nvidia chips. The commentary suggests a strong buy sentiment as the stock has shown parabolic movement recently.
Pessimistic View on Beyond Meat
"The fundamentals never lie. Over the long term, the stock price will always follow the fundamentals. A company like Beyond Meat is absolute poo poo, right? It\'s terrible. They don\'t have any customers. Anybody who doesn\'t like meat isn\'t eating processed chemicals. And anybody who likes meat isn\'t eating Beyond Meat. They\'ve got no customers."
The speaker delivers a scathing commentary on Beyond Meat, arguing that its fundamentals are extremely weak, with a lack of real customers and unsustainable business metrics, implying the stock is destined to perform poorly over time.
Bullish on Tesla Fundamentals
"And they short good companies with good management teams at bad prices. And I really think it\'s the quality of the company and the management team that matters the most. So like everyone who\'s short Tesla I think is making a gigantic mistake because it kind of fundamentally is a good company and it kind of fundamentally a great management team."
The speaker criticizes short sellers targeting Tesla, arguing that despite its high price, Tesla is a fundamentally strong company with an excellent management team. This serves as a warning against shorting what is portrayed as a fundamentally sound stock.
Long SPRB on Rare Disease Catalyst
"Why long SPRB? Well, this is my wheelhouse. Its a rare disease drug company and they have a rare disease from a drug from Biomearin. Biomearin was kind of like the rare disease kings and, um, yeah, basically, um, the drug works, um, really well and, um, itll get FDA approval and itll sell a lot and thats really it. Its worth like 5x what its trading at."
The speaker recommends a long position in SPRB, citing its rare disease focus and the potential for FDA approval as key catalysts. The claim is that the drug is undervalued, trading at approximately one-fifth of its potential value.
Short Beyond Meat Trade
"Let me see if I can short some more beyond. I'd short a little bit more beyond at like my average is around six. So short a little more. The bond holders are just shoving the stock in your face and that kind of makes it hard for their stock to rally. That's why I'm short it."
The speaker explicitly calls for increasing a short position in Beyond Meat (BYND), arguing that aggressive actions from bond holders are keeping the stock depressed and inhibiting a rally.
Shorting Beyond Meat on Broken Fundamentals
"I just shorted some. My average is 375 now. Um, it's, uh, this had been a profitable short for me years ago. Like, this is just such an AUG company that's like it's so reliable to short it. Um, 'cause again negative growth in terms of size of the portfolio. I think I'm at 1% now. So it would have to go literally 100x for me to be worried about it."
The speaker outlines his short position in Beyond Meat, noting that he has already entered at an average price of 375 and is comfortable keeping a 1% position given the company's persistently broken fundamentals and negative growth. He indicates a willingness to increase his short if the stock shows upward pressure, reinforcing his bearish view on the stock.
Short Trade Call on Beyond Meat due to Overextended Financials
"Beyond Meat, um that has rallied what a what a move from it was trading at 8 cents. This is the 2027 paper and it's now 75 cents on the dollar. Incredible, incredible move for the Beyond Meat debt. No real update on Spruce. Same same story. No, Beyond Meat isn't the GameStop of anything. Okay, so they're issuing up to... share outstanding number is wrong. It's not a 200 million market cap. Massive amount of stock. 326,190,370. They like quadruple the shares outstanding. So, what is this business worth? What's the stock price? 356. Um, yeah, the bonds have 10xed. Um, bond holders are allowed to put them into bankruptcy, but now company's kind of back, but you know, there's maybe 40 million in gross profit. I got some short on a different broker. Short at 345."
The speaker outlines a short trade on Beyond Meat (BYND), emphasizing its overblown valuation and financial distortions—quadrupled shares outstanding, inflated debt conversion, and weak gross profit metrics. The detailed rationale, including an executed short at 345, calls the stock a bankrupt candidate with unsustainable fundamentals.
Short Tesla Trade Call
"m short Tesla. Why isn"
The speaker highlights an active short position on Tesla, questioning the market behavior in light of his value investing approach. The brevity of the comment contrasts his strong conviction against the stock despite broader market trends.
Short CLSQ and Joby Trade Calls
"Plenty of stocks still up a ton. Maybe I should short CLSQ. I'm short Joby as well."
The speaker briefly considers additional short positions by mentioning a potential short on CLSQ along with an existing short on Joby. The comment reflects an opportunistic approach in a volatile market environment.
Short BTQ - Zero Value Warning
"e going to owe money. Listen, if you don"
The speaker declares a strong negative view on BTQ, calling the company worthless and predicting it will fall to near zero. The aggressive tone underscores a clear short trade recommendation, warning inexperienced traders.
Short Regetti Trade Call
"Expensive, man. I would just keep shorting Regetti. Regetti CEO is presenting at this conference."
The speaker explicitly recommends shorting Regetti, noting that the stock is expensive despite the CEO speaking at a conference. The suggestion implies that the company's fundamentals or valuation might be off.
Bearish Outlook on Publicly Traded Quantum Stocks
"And I think that, you know, the four publicly traded quantum stocks are all going to zero. I don't think there's any value in any of these companies. IMQ has tried hard to pivot by using its stock to buy other companies, but fundamentally, these stocks have no revenue and no real future. Even if capital is flowing in now, eventually the market will force a reckoning. It's a great time to start shorting because capital cycles shift fast."
The speaker delivers a strongly bearish view on publicly traded quantum stocks, asserting that all four listed quantum companies will eventually go to zero due to a lack of revenue and sustainable business models. The emphasis is on the imminent capital cycle reversal, signaling short opportunities for traders.
Bullish Call on ABVX with Target Price of 200
"Yeah, one stock I like. Come on, man. Come on. I like a stock called ABVX. I've been long, I've been longing the stock. I think it's going to go to 200. And that's really it. It's a drug company and I believe there's substantial upside."
The speaker expresses a clear bullish trade call on ABVX, stating a conviction that the stock will rise significantly to a target price of 200. The commentary identifies ABVX as a drug company and implies strong potential, making it an actionable idea for traders.
Trade Call: Buy QBTS at $7
"The trade is not buying QBQTs at at 34 bucks. The trade is buying QBTS at $7, riding the first phase of the quantum wave. Then, when it hangs, you rinse and repeat."
The speaker explicitly recommends buying QBTS at $7 as a way to capitalize on the early phase of the quantum computing wave. The emphasis is on entering at a lower price point rather than paying inflated prices, with the plan to exit after the initial surge.
Missed Quantum Trade Entry
"I'm not saying buy RTI at $48. So, I'm not seeing buy high Q at as at $70. You've already missed a trade when I pulled it at 750. The quantum trade from this perspective has already occurred. In other words, if you're waiting for an entry at these levels right now, you're too late."
The speaker offers an explicit trade call regarding quantum-oriented stocks. He dismisses buying RTI at $48 or high Q at $70, asserting that the optimal entry has passed, as he himself entered at 750. This retrospective call highlights his conviction that the quantum play, which involves companies linked to quantum computing and its associated infrastructure, is now a missed opportunity for new entrants.
Immediate Buy Signal for ANAB
"Yeah, I like ANAB. I looked at it. I can do uh I could do four. I could do right now. Yeah, chemistry is good to learn. No need for congratulations."
The speaker expresses a clear and immediate bullish trade call on ANAB, stating a personal readiness to buy at that moment based on a positive qualitative view.
Company Commentary on AMD's AI Accelerator Business
"Our recent conversations across the supply chain point to AMD experiencing slowing progress with its AI accelerator business. We think makes it increasingly challenging for them to meet over high expectations. This year conversations we show signs that AMD is struggling to grow for many of the customers that announced at its AI event this summer. Market remains challenging with highly demanding customers. Many of the headline customers have only purchased evaluation systems that are unlikely to convert into volume orders for at least one generation of MI systems."
The speaker provides an in-depth commentary on AMD, highlighting concerns regarding its AI accelerator business. He notes that despite a high-profile OpenAI-related event, AMD is facing challenges as many customers have only committed to evaluation systems rather than full volume orders, which could hinder future growth.
Speculative Outlook on Unicure Buyout Prospects
"Will my price target what would be your price target for cure in case of a bio here? Let's un let's let's understand this from a linguistics perspective first. What would be your price target for cure in case of a buyout conservatively? That is our question, right? Cure is not a cure for Huntington's to be clear. It's a treatment. It's a potential treatment without exactly definitive control data. So, it's speculative treatment. If a company were to be bought out, I mean, you can't, it doesn't make sense. What would your price target be? I guess what you're trying to ask is, do you think there is a drug company out there willing to pay a premium right now for Unicure stock price? I don't think that's the right way to think about it."
The speaker discusses the idea of setting a price target for Unicure in the event of a buyout. He clarifies that Unicure offers a speculative treatment for Huntington's rather than a definitive cure, emphasizing that drug companies are unlikely to pay a substantial premium without clear data. This commentary highlights the complexities behind M&A expectations and cautions investors against assuming a buyout scenario as a basis for valuation.
Automated Multi-Leg Trade Calls Using Custom Tool
"All right. So, it's telling me Cororeweave is a short microchip and Coreweave are shorts. So, I'm going to go put that trade in. Microchip. And I got a little ledger here. I'm going to use Got to go look up where I got out of actually. sell microchip do a small amount just a 100 shares 584 all right I could copy and paste this instead corweed as well so I'll do that core weed is a bigger stock price I think so I'm going to do less share amount half as much shares so 50 12977 um long that's uh healthcare company Molina so that's even bigger stock pricey uh 203945. Uh what is this one? 40. And then Futu wants me to go long this thing. Some kind of, okay, it's online brokerage. You guys heard of Futu FU TU? I guess I'll buy some."
The speaker details several explicit trade actions generated by his custom automated market analysis tool. He indicates short positions on Coreweave (and selling Microchip with specific share amounts and price references) and long positions on healthcare company Molina and online brokerage Futu. The trades are executed on an intraday basis with short time horizons, reflecting a systematic, quantitative intraday trading strategy.
Short Sound Hound Stock
"Sound Hound ... It's a joke. I mean, everyone on Wall Street knows Sound Hound's a scam. I didn't short sound. I'm just saying it's a good short."
The host dismisses Sound Hound as a scam and implies that it is an excellent candidate for a short position, highlighting its lack of credibility and value.
Avoid Long Position in MLTX
"MLTX big disappointment 88%. We didn't have the confidence uh either way of position like most of the street. I was thinking it maybe was long. It was not a long."
The speaker expresses strong disappointment with MLTX citing an '88% big disappointment' and explicitly rejects taking a long position on the stock, suggesting caution to investors.